Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology
|
Buy Now
Extending the Spectrum of Precompetitive Collaboration in Oncology Research - Workshop Summary (Paperback)
Loot Price: R1,096
Discovery Miles 10 960
|
|
Extending the Spectrum of Precompetitive Collaboration in Oncology Research - Workshop Summary (Paperback)
Expected to ship within 12 - 17 working days
|
Despite spending more time and money in developing novel
therapeutics, the success rate for new pharmacologic treatments has
been poor. Although the research and development expenditures have
grown 13 percent each year since 1970 (a 50-fold increase), the
number of new drugs approved annually is no greater now than it was
50 years ago. Over the past decade, skyrocketing costs and the
complexity of the scientific knowledge upon which to develop new
agents have provided incentives for alternative approaches to drug
development, if we are to continue to improve clinical care and
reduce mortality. These challenges create opportunities for
improved collaboration between industry, academia, government, and
philanthropic organizations at each stage in new drug development,
marketing, and implementation. Perhaps the most appropriate initial
step in addressing the need for collaboration is to consider more
precompetitive relationships that allow sharing of scientific
information to foster drug development. While these collaborative
relationships in basic and preclinical research on drug targets and
the early stages of clinical testing are acknowledged to be
potentially important drivers for innovation and more rapid
marketing of new agents, they also raise a number of concerns that
must be addressed. For example, acknowledgment of academic
productivity and independence and economic competitiveness must be
considered and these challenges managed to foster a culture of
collaboration. At the same time, regulatory issues, the need for
standardization, and intellectual property concerns must be
confronted if the current models for drug development are to be
refined to encourage robust participation in precompetitive
collaborations. Recognizing the growing importance of
precompetitive collaborations in oncology drug development, as well
as the challenges these innovative collaborations pose, the
National Cancer Policy Forum of the Institute of Medicine held a
workshop on February 9 and 10, 2010. This book is a summary of the
workshop proceedings. Table of Contents Front Matter Workshop
Summary Acronyms Glossary Appendix A: Workshop Agenda Appendix B:
Polling Results
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.